Compare Royal Bank of Canada (RY) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Bank of Canada vs Tango Therapeutics Inc. — how do they compare? Royal Bank of Canada trades at $193.47 (market cap $268.76B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Royal Bank of Canada is far larger — about 71.7× Tango Therapeutics Inc.'s market cap, and Royal Bank of Canada pays a 2.62% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royal Bank of Canada for 48 Days and Tango Therapeutics Inc. for 0 Days on average.
| RY | TNGX | |
|---|---|---|
Market Cap | $268.76B | $3.75B |
Volume | 726,877 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $217.87 | $32.90 |
52-Week Low | $145.31 | $7.50 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $737.27B | $2.77B |
Dividend Yield | 2.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Bank of Canada (RY) trades at $194.67, up 0.99% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.07 exceeding expectations. Revenue grew to $66.53B in 2025, and net income margin improved to 32.01%. Recent news highlights record Q3 2026 results and strategic initiatives like the unified Global Transaction Banking business.
Outlook remains positive with projected 2026 revenue of $71.1B and net income of $22.7B, though stretched valuations and technical bearishness pose risks. Analyst consensus is mixed with 43% buy ratings, but institutional buying activity supports confidence. Key risks include macroeconomic sensitivity and competitive pressures in the banking sector.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
